中文名 | Ridaforolimus (Deforolimus, MK-8669) |
英文名 | (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04, |
别名 | 药雷帕霉素 雷帕霉素衍生物 (二甲基亚膦酰)雷帕霉素 42-(二甲基亚膦酰)雷帕霉素 (二甲基亚膦酰)雷帕霉素合成) MTOR抑制剂(DEFOROLIMUS) 42-(二甲基亚膦酰)雷帕霉素, 一种有效和选择性MTOR抑制剂 |
英文别名 | Deforolimus Ridaforolimus Deforolimus (AP23573) RIDAFOROLIMUS DEFOROLIMUS DeforoliMus (RidaforoliMus) Deforolimus (AP23573, MK-8669) 42-(Dimethylphosphinate)rapamycin Ridaforolimus (Deforolimus, MK-8669) DeforoliMus(AP 23573,MK-8669,RidaforoliMus) (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04, |
CAS | 572924-54-0 |
化学式 | C53H84NO14P |
分子量 | 990.21 |
密度 | 1.18±0.1 g/cm3(Predicted) |
熔点 | 95-98°C |
沸点 | 996.2±75.0 °C(Predicted) |
溶解度 | DMSO (微溶) 、甲醇 (微溶) |
酸度系数 | 10.40±0.70(Predicted) |
存储条件 | Hygroscopic, -20°C Freezer, Under Inert Atmosphere |
稳定性 | 吸湿性 |
外观 | 固体 |
颜色 | Off-White to Pale Yellow |
体外研究 | 使用Deforolimus处理HT-1080细胞,抑制S6和4E-BP1磷酸化, 这种作用存在剂量依赖性,IC50分别为0.2 nM和5.6 nM, EC50分别为0.2 nM 和1.0 nM, 且导致细胞尺寸降低,G1期细胞增多,和抑制葡萄糖摄取,EC50为0.1-1 nM。Deforolimus作用于一组细胞系,具有显著抗增殖活性,EC50为0.2-2.3 nM。Deforolimus 有效且选择性抑制VEGF产量,这种作用存在剂量依赖性, EC50为~0.1 nM。 Deforolimus作用于人NSCLC细胞系(除了 H157细胞),显著抑制细胞生长,IC30为2.45-8.83 nM,而作用于H157细胞时,IC30 >20 nM。2.8-5.9 nM Deforolimus处理A549, H1703和H157细胞(除了表达mTORC1耐药变异的H1666),使 p70S6KThr389去磷酸化,且作用于A549和H1703细胞,提高 pAKTser473和pAKTThr308磷酸化水平。Deforolimus和MEK抑制剂CI-1040或 PD0325901 联用处理人肺癌细胞系,具有协同作用,这种作用存在剂量依赖性,这种作用与细胞增殖受抑制而不是细胞死亡增多相关,处理24小时后,抑制40%核糖体合成,且使多核糖体/染色单体比例下降。 |
体内研究 | Deforolimus处理携带PC-3 (前列腺), HCT-116 (结肠), MCF7 (胸腺), PANC-1 (胰腺)或A549 (肺) 移植瘤的小鼠,具有显著抗癌效果,这种作用存在剂量依赖性,且作用于SK-LMS-1移植瘤,抑制mTOR信号。 |
参考资料 展开查看 | 1: Blay JY. Updating progress in sarcoma therapy with mTOR inhibitors. Ann Oncol. 2010 Jun 29. [Epub ahead of print] PubMed PMID: 20591820. 2: Penel N, Watelle F, Vanhuyse M, Adenis A. [Treatment of adult patients with metastatic sarcoma: current shift in concepts]. Bull Cancer. 2010 Jun 1;97(6):687-91. French. PubMed PMID: 20462829. 3: Rodriguez-Pascual J, Cheng E, Maroto P, Duran I. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs. 2010 Jun;21(5):478-86. Review. PubMed PMID: 20401967. 4: Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 2010 Apr;7(4):209-19. Epub 2010 Mar 16. PubMed PMID: 20234352. 5: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Nov;31(9):597-633. PubMed PMID: 20094643. 6: Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol. 2009 Dec;36 Suppl 3:S3-S17. Review. PubMed PMID: 19963098. 7: Sessa C, Tosi D, Viganò L, Albanell J, Hess D, Maur M, Cresta S, Locatelli A, Angst R, Rojo F, Coceani N, Rivera VM, Berk L, Haluska F, Gianni L. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol. 2010 Jun;21(6):1315-22. Epub 2009 Nov 9. PubMed PMID: 19901013. 8: Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characteriza |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.01 ml | 5.049 ml | 10.099 ml |
5 mM | 0.202 ml | 1.01 ml | 2.02 ml |
10 mM | 0.101 ml | 0.505 ml | 1.01 ml |
5 mM | 0.02 ml | 0.101 ml | 0.202 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!